Engineering T cells to outsmart cancer.
How can we help immune cells overcome cancer? At Gustave Roussy, we combine CRISPR screening and T-cell engineering to turn that question into new therapeutic strategies.
Exploring the potential of living therapies
Understand the barriers.
Expand the possibilities.
Find what holds T cells back.
Use in vivo CRISPR screening to investigate the factors that limit immunity inside tumors.
CRISPR screening EngineerBuild on the biology.
Explore CAR-T strategies and edit tumor-infiltrating lymphocytes to improve their function.
T-cell engineering AdvanceConnect discovery to therapy.
Bring functional genomics and synthetic immunology together to inform future cell therapies.
Research publications
Dr. Laurie Menger
Laurie is an INSERM researcher and young group leader of the Advanced T-cell Therapy team (U1356) at Gustave Roussy, specialized in Onco/Immunobiotechnology. She has built her career on multidisciplinary approaches to drive immunotherapeutic projects toward translational development. In 2019 she obtained an ANR Jeune Chercheur grant, and in 2021 an ATIP-Avenir (INSERM) and a Gustave Roussy starting package. Her research feeds two flagship medico-scientific programs: precision medicine (PRISM) and Innovative Therapeutics.
Meet Laurie Menger
in the lab.
In this short video from Gustave Roussy, Laurie introduces the Advanced T-cell Therapy team and its research. In French, with English subtitles.
What we do
Research at a glance
In vivo CRISPR screening
Our team was the first in Europe to establish in vivo CRISPR-Cas9 screening in primary T cells, building a functional pipeline for the systematic, unbiased characterization of the factors that limit T-cell function in complex immunosuppressive environments.
Engineering CAR-T therapies
We integrate genome-wide CRISPR activation, editing of tumour-infiltrating lymphocytes and combinatorial CAR strategies to design more effective, safer and more affordable adoptive cell therapies against cancer.
Synthetic immunology
By modulating the epigenetic regulators of the antitumor response and combining metabolic and single-cell profiling, we turn the biology of T cells into a programmable platform for synthetic immunology.
Bring your curiosity.
Help shape what comes next.
We bring together immunology, biotechnology and data science to explore new directions in cancer immunotherapy. Get to know the people behind the research.
With the support of
Our research is funded by
